Ubs Group Ag Akebia Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 153,662 shares of AKBA stock, worth $275,054. This represents 0.0% of its overall portfolio holdings.

Number of Shares

153,662

Previous 142,828 7.59%

Holding current value

$275,054

Previous $145,000 39.31%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $10,183 - $16,792	10,834 Added 7.59%	153,662 $202,000
Q2 2024 Aug 13, 2024	BUY	$0.86 - $1.63 $37,401 - $70,888	43,490 Added 43.78%	142,828 $145,000
Q1 2024 May 13, 2024	SELL	$1.27 - $2.24 $73,268 - $129,230	-57,692 Reduced 36.74%	99,338 $181,000
Q4 2023 Feb 09, 2024	BUY	$0.8 - $1.28 $70,641 - $113,026	88,302 Added 128.48%	157,030 $194,000
Q3 2023 Nov 09, 2023	SELL	$0.87 - $1.84 $2,401 - $5,078	-2,760 Reduced 3.86%	68,728 $78,000
Q2 2023 Aug 11, 2023	SELL	$0.51 - $1.43 $8,408 - $23,576	-16,487 Reduced 18.74%	71,488 $65,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.15 $16,363 - $33,603	29,220 Added 49.73%	87,975 $49,000
Q4 2022 Feb 08, 2023	SELL	$0.25 - $0.58 $18,301 - $42,459	-73,206 Reduced 55.48%	58,755 $34,000
Q3 2022 Nov 10, 2022	BUY	$0.3 - $0.46 $392 - $602	1,309 Added 1.0%	131,961 $41,000
Q2 2022 Aug 10, 2022	SELL	$0.32 - $0.67 $204,411 - $427,986	-638,786 Reduced 83.02%	130,652 $46,000
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $206,487 - $840,288	286,788 Added 59.42%	769,438 $553,000
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $104,400 - $154,291	-46,195 Reduced 8.74%	482,650 $1.09 Million
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $917,649 - $1.52 Million	390,489 Added 282.23%	528,845 $1.52 Million
Q2 2021 Aug 13, 2021	SELL	$2.83 - $4.2 $537,487 - $797,685	-189,925 Reduced 57.85%	138,356 $524,000
Q1 2021 May 12, 2021	BUY	$2.92 - $5.06 $560,739 - $971,692	192,034 Added 140.95%	328,281 $1.11 Million
Q4 2020 Feb 11, 2021	SELL	$2.22 - $3.78 $75,071 - $127,824	-33,816 Reduced 19.88%	136,247 $381,000
Q3 2020 Nov 12, 2020	BUY	$2.39 - $13.08 $94,973 - $519,773	39,738 Added 30.49%	170,063 $427,000
Q2 2020 Jul 31, 2020	SELL	$6.67 - $13.58 $181,170 - $368,859	-27,162 Reduced 17.25%	130,325 $1.77 Million
Q1 2020 May 01, 2020	SELL	$4.1 - $10.24 $266,864 - $666,511	-65,089 Reduced 29.24%	157,487 $1.19 Million
Q4 2019 Feb 14, 2020	SELL	$3.16 - $6.73 $297,081 - $632,707	-94,013 Reduced 29.7%	222,576 $1.41 Million
Q3 2019 Nov 14, 2019	BUY	$3.55 - $5.4 $218,964 - $333,072	61,680 Added 24.2%	316,589 $1.24 Million
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $439,007 - $861,953	107,075 Added 72.43%	254,909 $1.23 Million
Q1 2019 May 14, 2019	SELL	$5.41 - $8.73 $196,485 - $317,064	-36,319 Reduced 19.72%	147,834 $1.21 Million
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $131,278 - $222,857	24,356 Added 15.24%	184,153 $1.02 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $205,916 - $294,760	27,677 Added 20.95%	159,797 $1.41 Million
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $551,095 - $682,996	-60,229 Reduced 31.31%	132,120 $1.32 Million
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $728,854 - $1.2 Million	76,480 Added 66.01%	192,349 $1.83 Million
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $562,351 - $773,628	39,491 Added 51.7%	115,869 $1.72 Million
Q3 2017 Nov 14, 2017	SELL	$13.06 - $19.67 $455,715 - $686,364	-34,894 Reduced 31.36%	76,378 $1.5 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-40,374 Reduced 26.62%	111,272 $1.6 Million
Q1 2017 Nov 14, 2017	BUY	N/A	151,646	151,646 $1.4 Million

Others Institutions Holding AKBA

# of Institutions

120

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account